Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients
and are poor prognostic factors. Controversy exists regarding the potential of …

Background Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

A higher risk of thrombosis has been described as a prominent feature of coronavirus
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated
with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Background The incidence of venous thromboembolic events (VTE) in patients with COVID-
19 is generally high but varies markedly. However, the relationship between anticoagulation …